http://www.cureffi.org/2024/03/24/huntingtons-aso-trial-halted/ WebMar 22, 2024 · Huntington’s disease is a rare genetic, progressive condition that causes the nerve cells in the brain to break down, causing problems with a person’s ability to think, …

Roche Designing New Phase 2 Trial of Tominersen in Huntington Disease

WebJan 30, 2024 · The Clinical Community Reaction to Roche’s Tominersen Turnaround in Huntington. Jan 30, 2024. Matt Hoffman. After discontinuing dosing in the phase 3 … WebMar 22, 2024 · South San Francisco, CA -- March 22, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the decision to discontinue dosing in the Phase III GENERATION HD1 study of … city of potwin kansas

Ionis

Web11/18/21, 1:57 PM At Risk for Huntington's Disease: Roche: less frequent dosing for Phase 3 Huntington’ s clinical trial, easing burden on patients ... it will reduce the frequency of dosing in its historic Phase 3 Huntington’s disease gene-silencing clinical trial, thus easing the burden on the participants, their families, and clinics. WebJan 24, 2024 · On 18 January, Ionis Pharmaceuticals announced that its partner Roche would begin a new Phase II trial to reassess its pipeline antisense therapy, tominersen, in … WebMar 12, 2024 · A Phase 1 clinical trial testing Roche ’s investigational therapy tominersen for Huntington’s disease has been placed on hold after two cases of infection were found during the study. The infections were linked to the device used to take samples of patients’ cerebrospinal fluid (CSF, the liquid surrounding the brain and spinal cord), and ... city of poughkeepsie birth records